Nature communications · 2025
Targeting microRNA-dependent control of X chromosome inactivation improves the Rett Syndrome phenotype.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lou Song, DJiake Tihagam Rachisan, Wasko Urszula N, Equbal Zaffar, Venkatesan Sanjay, Braczyk Klaudia, Przanowski Piotr, Il Koo Bon, Saltani Ilyas, Singh Arjun Tushir, Likhite Shibi, Powers Samantha, Souza George M P R, Maxwell Robert A, Yu Jun, Zhu Lihua J, Beenhakker Mark, Abbott Stephen B G, Lu Zhipeng, Green Michael R, Meyer Kathrin C, Tushir-Singh Jogender, Bhatnagar Sanchita
Аннотация
X chromosome inactivation (XCI) is induced by Xist long non-coding RNA and protein-coding genes. However, the role of small non-coding RNA function in XCI remains unidentified. Our genome-wide, loss-of-function CRISPR/Cas9 screen in female fibroblasts identified microRNAs (miRNAs) as regulators of XCI. A striking finding is the identification of miR106a among the top candidates from the screen. Loss of miR106a is accompanied by altered Xist interactome, leading to dissociation and destabilization of Xist. XCI interference via miR106a inhibition has therapeutic implications for Rett syndrome (RTT) girls with a defective X-linked MECP2 gene. Here, we discovered that the inhibition of miR106a significantly improves several facets of RTT pathology: it increases the life span, enhances locomotor activity and exploratory behavior, and diminishes breathing variabilities. Our results suggest that miR106a targeting offers a feasible therapeutic strategy for RTT and other monogenic X-linked neurodevelopmental disorders.